NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation; Academy of Science of South Africa. The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa: Global and Local Challenges and Solutions: Summary of a Joint Workshop. Washington (DC): National Academies Press (US); 2011.

Cover of The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa

The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa: Global and Local Challenges and Solutions: Summary of a Joint Workshop.

Show details


  1. Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of initiation of antiretroviral drugs during tuberculosis therapy. New England Journal of Medicine. 2010;362(8):697–706. [PMC free article: PMC3076221] [PubMed: 20181971]
  2. Adams S, Ehrlich R, van Zyl Smit R, Dawson R, Said-Hartley Q, Dheda K. Mycobacterium tuberculosis infection in health workers at primary care facilities in the Western Cape. Paper presented at 2nd South African Tuberculosis Conference; Durban, South Africa. 2010.
  3. Association of Public Health Laboratories and Public Health Informatics Institute. Requirements Document for Public Health Laboratory Information (LIM) Systems. Washington, DC: Association of Public Health Laboratories; 2003.
  4. Basu S, Andrews J, Poolman E, Gandhi N, Shah N, Moll A, Moodley P, Galvani A, Friedland G. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: An epidemiological modelling study. Lancet. 2007;370(9597):1500–1507. [PMC free article: PMC3711808] [PubMed: 17964351]
  5. Brust JCM, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. The International Journal of Tuberculosis and Lung Disease. 2010;14:413–419. [PMC free article: PMC3005763] [PubMed: 20202298]
  6. Diacon A, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino J, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Neeley D. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. New England Journal of Medicine. 2009;360(23):2397–2405. [PubMed: 19494215]
  7. DoH (Department of Health, Republic of South Africa). Tuberculosis strategic plan for South Africa, 2007-2011. 2007. [September 7, 2010]. http://www​​/uploads/files/tb_strategic_plan_indd​.pdf.
  8. Drobac P, Mukherjee J, Joseph K, Mitnick C, Furin J, del Castillo H, Shin S, Becerra M. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006;117(6):2022–2029. [PubMed: 16740844]
  9. Falzon D, Zignol M, Nkhoma W, van Gemert W, Wright A, Jaramillo E. An update on drug-resistant tuberculosis in Africa. Presentation at the 40th Union World Conference on Lung Health; Cancun, Mexico. 2009.
  10. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9547):1575–1580. [PubMed: 17084757]
  11. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH., on behalf of the Tugela Ferry Care and Research (TF CARES) Collaboration. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. American Journal of Respiratory and Critical Care Medicine. 2010;181(1):80–86. [PubMed: 19833824]
  12. Haley CE, McDonald RC, Rossi L, Jones WD Jr, Haley RW, Luby JP. Tuberculosis epidemic among hospital personnel. Infection Control and Hospital Epidemiology. 1989;10(5):204–210. [PubMed: 2738388]
  13. IOM (Institute of Medicine). Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge: Workshop Summary. Washington, DC: The National Academies Press; 2009. [PubMed: 20669505]
  14. Jarand J, Shean K, O'Donnell M, Loveday M, Kvasnovsky C, van der Walt M, Adams S, Willcox P, O'Grady J, Zumla A, Dheda K. Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Tropical Medicine and International Health. 2010;15(10):1179–1184. [PubMed: 20831672]
  15. Johnson R, Warren R, Strauss O, Jordaan A, Falmer A, Beyers N, Schaaf H, Murray M, Cloete K, van Helden P, Victor T. An outbreak of drug resistant tuberculosis caused by a Beijing strain in the Western Cape, South Africa. International Journal of Tuberculosis and Lung Disease. 2006;10(12):1412–1414. [PubMed: 17167961]
  16. Johnson R, Warren R, van der Spuy G, Gey van Pittius N, Theron D, Streicher E, Bosman M, Coetzee G, van Helden P, Victor T. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. International Journal of Tuberculosis and Lung Disease. 2010;14:119–121. [PubMed: 20003705]
  17. Kenyon TA, Valway SE, Ihle WW, Onorato IM, Castro KG. Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight. New England Journal of Medicine. 2009;334(15):933–938. [PubMed: 8596593]
  18. Keshavjee S, Seung K. Stemming the tide of multidrug-resistant tuberculosis: Major barriers to addressing the growing epidemic. 2008. [September 7, 2010]. http://www​.brighamandwomens​.org/socialmedicine​/News/IOM_MDRTB​_whitepaper_2009_01_14_FINAL_Edited.pdf.
  19. Kvasnovsky CL, Dalton TL, Lancaster JL, Brand JD, Cegielski JP, van der Walt ML. Early mortality among MDR- and XDR-TB patients in KwaZulu-Natal Province, South Africa. Abstract presented at 39th World IUATLD Conference; Paris, France. 2008.
  20. Kvasnovsky CL, Ershova JE, Borisov A, Kurbatova K, Dalton TL, Campos-Caoili J, Cegielski JP., for PETTS (Preserving Effective TB Treatment Study) investigators. Effect of second-line drug resistance on treatment outcome among MDR TB patients in PETTS study. Abstract presented at the 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union); Cancun, Mexico. 2009.
  21. Kvasnovsky CL, Cegielski JP, Erasmus R, Siwisa NO, Thomas K, van der Walt ML. High mortality in HIV-positive and HIV-negative patients with XDR-TB in Eastern Cape, South Africa. Abstract presented at the 41st World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union); Berlin, Germany. 2010.
  22. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an anti-retroviral treatment programme in sub-Saharan Africa: Impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20(12):1605–1612. [PubMed: 16868441]
  23. Lawn S, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clinics in Chest Medicine. 2009;30:685–689. [PMC free article: PMC2887494] [PubMed: 19925961]
  24. Lawn S, Wood R, De Cock K, Kranzer K, Lewis J, Churchyard G. Complementary roles of antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in resource-limited settings. Lancet Infectious Diseases. 2010;10:489–498. [PubMed: 20610331]
  25. Mac-Arthur A Jr, Gloyd S, Perdigão P, Noya A, Sacarlal J, Kreiss J. Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique. International Journal of Tuberculosis and Lung Disease. 2001;5:894–902. [PubMed: 11605881]
  26. Maus CE, Plikaytis BB, Shinnick TM. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2005;49(2):571–577. [PMC free article: PMC547314] [PubMed: 15673735]
  27. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. 2010. [September 13, 2010]. http://www​​.pdf.
  28. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, Codecasa LR, Spanevello A, Cirillo DM., S.T.S. Group. Fluoroquinolones: Are they essential to treat multidrug-resistant tuberculosis? European Respiratory Journal. 2008;31(4):904–905. [PubMed: 18378786]
  29. Moll T, Gandhi N, Sturm AW, Andrews J, Shah NS, Lalloo U, Moodley P, Friedland G. Extensively drug-resistant (XDR) TB now more common than MDR TB in Tugela Ferry, KwaZulu-Natal, South Africa. Abstract presented at the 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union); Cape Town, South Africa. 2007.
  30. Nugent R, Back E, Beith A. The race against drug resistance: A report of the center for global development's drug resistance working group. 2010. [August 17, 2010]. http://www​​/content/publications/detail/1424207/
  31. Nunes EA, De Capitani EM, Coelho E, Joaquim OA, Figueiredo IRO, Cossa AM, Panunto AC, Carvalho-Ramos M. Patterns of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002-2003. International Journal of Tuberculosis and Lung Disease. 2005;9:494–500. [PubMed: 15875919]
  32. O'Donnell M, Padayatchi N, Master I, Osburn G, Horsburgh C. Improved early results for patients with extensively drug resistant tuberculosis and HIV in South Africa. International Journal of Tuberculosis and Lung Disease. 2009;13(7):855–861. [PMC free article: PMC2855970] [PubMed: 19555535]
  33. Parida SK, Kaufmann SHE. The quest for biomarkers in tuberculosis. Drug Discovery Today. 2010;15(3-4):148–157. [PubMed: 19854295]
  34. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clinical Infectious Diseases. 2007;45(11):1409–1414. [PubMed: 17990220]
  35. Riley R, Mills C, Nyka W, Weinstock N, Storey P, Sultan L, Riley M, Wells W. Aerial dissemination of pulmonary tuberculosis: A two year study of contagion in a tuberculosis ward. American Journal of Epidemiology. 1959;142(1):3–14. [PubMed: 7785671]
  36. Schaaf HS, Botha P, Gie RP, Vermeulen HA, Coetzee GJ, Donald PR. The 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa. Tropical Medicine and International Health. 1996;1(5):718–722. [PubMed: 8911459]
  37. Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: Diagnostic delay, clinical features, and outcome. Archives of Disease in Childhood. 2003;88(12):1106–1111. [PMC free article: PMC1719385] [PubMed: 14670781]
  38. Shean K. Challenges Facing Health Care Workers Within the Health Systems in Which They Work. Speaker presentation at the Institute of Medicine Workshop on the Emerging Threat of Multidrug-Resistant Tuberculosis: Global and Local Challenges and Solutions; March 4, 2010; Pretoria, South Africa. 2010.
  39. Shisana O, Hall E, Maluleke K, Stoker D, Schwabe C, Colvin M, Chauveau J, Botha C, Gumede T, Fomundam H, Shaikh N, Rehle T, Udjo E, Gisselquist D. The impact of HIV/AIDS on the health sector. Pretoria, South Africa: National Department of Health; 2003.
  40. Strauss O, Warren R, Jordaan A, Streicher E, Hanekom M, Falmer A, Albert H, Trollip A, Hoosain E, van Helden P, Victor T. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. Journal of Clinical Microbiology. 2008;46:1514–1516. [PMC free article: PMC2292903] [PubMed: 18272712]
  41. Streicher E, Warren R, Kewley C, Simpson J, Rastogi N, Sola C, van der Spuy G, van Helden P, Victor T. Genotypic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from rural districts of the Western Cape Province of South Africa. Journal of Clinical Microbiology. 2001;42:891–894. [PMC free article: PMC344460] [PubMed: 14766882]
  42. TBCTA (Tuberculosis Coalition for Technical Assistance). International Standards for Tuberculosis Care (ISTC). second. The Hague, Netherlands: TBCTA; 2009.
  43. UN (United Nations). The millennium development goals report 2010. 2010. [August 10, 2010]. http://www​
  44. UNAIDS (Joint United Nations Programme on HIV/AIDS). 2008 report on the global AIDS epidemic. 2008. [September 7, 2010]. http://www​​/en/KnowledgeCentre​/HIVData/GlobalReport​/2008/2008_Global_report.asp.
  45. USAID (United States Agency for International Development). Mozambique: Tuberculosis Profile. 2009. [December 17, 2010]. http://www​​/our_work/global_health​/id/tuberculosis/countries​/africa/mozambique_profile.html.
  46. van der Walt ML, Lancaster JL, Weyer K, Becker P. Mortality among patients with multidrug-resistant tuberculosis (MDR TB) in South Africa. Abstract presented at the 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union); Cape Town, South Africa. 2007.
  47. van Helden PD. TB Diagnostics. Speaker presentation at the Institute of Medicine Workshop on The Emerging Threat of Multidrug-Resistant Tuberculosis: Global and Local Challenges and Solutions; March 4; Pretoria, South Africa. 2010.
  48. van Rie A, Warren R, Beyers N, Gie R, Classen C, Richardson M, Sampson S, Victor T, van Helden P. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling “strain w” among noninstitutionalized, human immunodeficiency virus-seronegative patients. Journal of Infectious Diseases. 1999;180:1608–1615. [PubMed: 10515823]
  49. Victor T, Streicher E, Kewley C, Jordaan A, van der Spuy G, Bosman M, Louw H, Murray M, Young D, van Helden P, Warren R. Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the Western Cape of South Africa. International Journal of Tuberculosis and Lung Disease. 2007;11:195–201. [PubMed: 17263291]
  50. Wells C, Cegielski J, Nelson L, Laserson K, Holtz T, Finlay A, Castro K, Weyer K. HIV infection and multidrug resistant tuberculosis—the perfect storm. Journal of Infectious Diseases. 2007;196(S1):S86–S107. [PubMed: 17624830]
  51. Weyer K, Lancaster J, Brand J, van Der Walt M, Levin J. Survey of tuberculosis drug resistance in South Africa 2001-2002. 2004. [September 7, 2010]. http://www​.sahealthinfo​.org/tb/natsurvey.pdf.
  52. WHO (World Health Organization). Tuberculosis facts update. 2009. [September 7, 2010]. http://www​​/assets/documents/resources​/factsheets/tbfactsheet​_2009update_one_page.pdf.
  53. WHO. Pathways to better diagnostics for tuberculosis: A blueprint for the development of TB diagnostics by the new diagnostics working group of the Stop TB partnership. Geneva, Switzerland: WHO; 2009.
  54. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. 2010. [September 7, 2010]. http://whqlibdoc​.who​.int/publications/2010​/9789241599191_eng.pdf.
  55. WHO. Global laboratory initiative. 2010. [September 7, 2010]. http://www​​/dots/laboratory/gli/en/
  56. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach—2010 rev. Geneva, Switzerland: WHO; 2010. [PubMed: 23741771]
  57. WHO. Factsheet: Tuberculosis diagnostics automated DNA test. 2010. [December 29, 2010]. http://www​​/features_archive/new_rapid_test​/en/index.html.
  58. WHO. Guidance on ethics of tuberculosis prevention, care and control. Geneva, Switzerland: WHO; 2010.
Copyright © 2011, National Academy of Sciences.
Bookshelf ID: NBK55586


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (750K)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...